THE RATE AND OUTCOMES OF REDUCING RE-HOSPITALIZATIONS WITH A TREATMENT REGIMEN INCLUDING DAPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION WITHOUT DIABETES PATIENTS

Tóm tắt

Background: Heart failure, a cardiovascular disease with a substantial disease burden, often leads to frequent hospitalizations for acute episodes. The readmission rate is estimated to be around 30-50%, resulting in high costs for both pharmacological and non-pharmacological treatments. Additionally, heart failure is associated with a considerable mortality rate, ranging from 48-57%. Objectives: To describe the rate and outcomes of reducing hospital readmissions for heart failure in non-diabetes patients and with heart failure featuring reduced ejection fraction, through the use of Dapagliflozin at Can Tho University of Medicine and Pharmacy Hospital. Materials and methods: A cross-sectional descriptive study was conducted 44 non-diabetes and heart failure with reduced ejection fraction patients who were examined and treated at Can Tho University of Medicine and Pharmacy Hospital. Results: The average age of patients was 67.3 ± 13, with male patients representing 65.9%. Shortness of breath was the most common symptom (77.3%). Other frequently observed symptoms included distended neck veins, peripheral edema, and rales in the lungs. The average ejection fraction was 36.65 ± 8.16%. In terms of functional classification, NYHA III represents the highest proportion at 54.5%. The median NT-proBNP concentration was 8757 pg/mL (ranging from a minimum of 604 pg/mL to a maximum of 35.000 pg/mL). The observed improvement rate in NYHA classification after treatment was 13.6%. The rate of rehospitalization for heart failure before treatment was 27.3%, decreasing to 11.4% after treatment (p=0.118 but the analysis suggests that there were no independent risk factors contributing to rehospitalization for heart failure in patients with reduced ejection fraction without diabetes.Conclusions: Dyspnea was the most common symptom in patients with heart failure with reduced ejection fraction and nondiabetes. The rate of rehospitalization for heart failure after 12 weeks of Dapagliflozin treatment was lower than before treatment, but this difference was not statistically significant.